5.15.19 MOCA celebrated 20 years of progress – and new milestones in ovarian cancer research funding – at our MOCA Annual Meeting this week.
This year, MOCA awarded $680,000 in funding to Minnesota and national researchers, putting our total amount of funding at nearly $9 million.
The 2019 MOCA-funded researchers include:
- Melissa Geller, M.D., M.S., University of Minnesota. “IL-15 superagonist ALT 803 maintenance therapy to prevent recurrence of advanced stage ovarian cancer.” $100,000 for one year.
- Xinyan Wu, Ph.D., Mayo Clinic. “A humanized antibody against AXL receptor tyrosine kinase as a novel therapy for ovarian cancer.” $100,000 for one year.
- Emil Lou, M.D., Ph.D., University of Minnesota. “Targeting channels of ovarian tumor cell communication.” $80,000 for one year.
- Valentina Zanfagnin, M.D., Mayo Clinic. “Repurposing ceritinib to enhance the efficacy of Olaparib in ovarian cancer.” $100,000 for one year.
- Reuben Harris, Ph.D. Mayo Clinic and University of Minnesota. “Diagnosing and targeting APOBEC3B in clear cell ovarian carcinoma.” $100,000 for one year.
- Naoko Sasamoto, M.D., M.P.H., Brigham and Women’s Hospital, Boston, MA. “High throughput protemics profiling for identification of early detection biomarkers of high-grade serous ovarian cancer.” National Early Detection Research Grant Award. $50,000 for one year.
- Amy Skubitz, Ph.D., University of Minnesota. “Verification of a biomarker panel for the early detection of ovarian cancer using serum samples from multiple sources.” $150,000 for one year.
In addition to the 2019 funding, MOCA is also providing $475,000 this year to multi-year grant awards that were funded in 2017 and 2018.
Curious to hear from the researchers themselves? Watch our Facebook Live video from the event!